Non-Responders to Intravitreal Ranibizumab in Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Conclusion: Data indicate a low proportion of functional and anatomical non-responders to IVRI. Further studies are warranted providing a better definition of non-responder and a clearer picture of the magnitude of response, when present.Ophthalmic Res (Source: Ophthalmic Research)
Source: Ophthalmic Research - September 30, 2016 Category: Opthalmology Source Type: research

Choroidal neovascular membrane in a treated choroidal hemangioma
Chokkahalli K Nagesha, Jaydeep Avinash Walinjkar, Vikas KhetanIndian Journal of Ophthalmology 2016 64(8):606-608Association of choroidal neovascular (CNV) membrane with circumscribed choroidal hemangioma is rare, and the CNV development after photodynamic therapy (PDT) is also rare. Etiopathogenesis of these associations is poorly understood. We noted the development of CNV over choroidal hemangioma after PDT therapy in a young female patient in our hospital. Temporal association of CNV development after PDT treatment points toward the possible side effects of PDT. Repeat injections of antivascular endothelial growth facto...
Source: Indian Journal of Ophthalmology - September 30, 2016 Category: Opthalmology Authors: Chokkahalli K Nagesha Jaydeep Avinash Walinjkar Vikas Khetan Source Type: research

The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab
Conclusions: The study showed that after IVR or IVB treatment, vascularization could be completed with delay; there were no differences in this delay time between the ranibizumab and bevacizumab groups. Besides, avascular areas may remain in the peripheral retina, and additional treatment may be necessary after IVB or IVR treatment. When the treatment was applied as monotherapy, more recurrence was observed in the ranibizumab group.Ophthalmologica (Source: Ophthalmologica)
Source: Ophthalmologica - September 29, 2016 Category: Opthalmology Source Type: research

Retinal pigment epithelial tear after intravitreal ranibizumab treatment for neovascular age-related macular degeneration
Conclusion: PED type and nAMD subtype are associated with the development of RPE tears after intravitreal ranibizumab injections. Continued ranibizumab therapy after RPE tear development can maintain visual acuity when the fovea is not involved. (Source: RETINA)
Source: RETINA - September 24, 2016 Category: Opthalmology Tags: Original Study Source Type: research

Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab
ConclusionsAbout 80  % of eyes with PCV require retreatment within 5 years after combination therapy with PDT and IVR. Retreatment is associated with older age and male gender and is related to reduced improvement of visual acuity. (Source: Japanese Journal of Ophthalmology)
Source: Japanese Journal of Ophthalmology - September 23, 2016 Category: Opthalmology Source Type: research

Short ‐term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients
ConclusionRanibizumab was effective in improving BCVA and was well tolerated in Japanese patients with BRVO and CRVO. The findings from this study were consistent with those reported in the Caucasian population. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 22, 2016 Category: Opthalmology Authors: Motohiro Kamei, Hiroko Terasaki, Nagahisa Yoshimura, Fumio Shiraga, Yuichiro Ogura, Andrea Suhner Grotzfeld, Stefan Pilz, Tatsuro Ishibashi Tags: Original Article Source Type: research

Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration
This study aimed to analyse changes in best corrected visual acuity (BCVA) and anatomical parameters in patients switching from a pro re nata (PRN) to a TE regimen during routine clinical practice. Methods Retrospective, consecutive, comparative case series of treatment-naïve patients who were initially treated with 0.5 mg ranibizumab according to a PRN schedule, and subsequently switched to a TE schedule (12-month follow-up). Results 146 eyes from 134 consecutive treatment-naïve patients were included. Mean BCVA (decimal±SD) increased from 0.39±0.23 to 0.55±0.22 (p
Source: British Journal of Ophthalmology - September 22, 2016 Category: Opthalmology Authors: Hatz, K., Prünte, C. Tags: Retina Original articles - Clinical science Source Type: research

Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselves
Aims To evaluate the presence of cognitive bias among retinal specialists when recommending treatment options for cystoid macular oedema (CMO) secondary to retinal vein occlusion (RVO). Methods Two randomly chosen samples of retina specialists were surveyed regarding their treatment and dosing regimen choices among three antivascular endothelial growth factor (anti-VEGF) biologics (aflibercept, bevacizumab and ranibizumab), intravitreal steroid, focal laser and observation for the treatment of CMO secondary to RVO. The first group was asked to make recommendations for two hypothetical patients: one with CMO secondary to b...
Source: British Journal of Ophthalmology - September 22, 2016 Category: Opthalmology Authors: Wang, M. D., Jeng-Miller, K. W., Feng, H. L., Prenner, J. L., Fine, H. F., Shah, S. P. Tags: Retina Original articles - Clinical science Source Type: research

Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre
Conclusion Combination of vPDT and intravitreal anti-VEGF (ranibizumab/bevacizumab) was associated with better visual outcomes and higher rates of regression in eyes with myopic CNV as compared with monotherapy with PDT or anti-VEGF. Larger size of CNV, and high refractive error were independent risk factors for poor visual outcomes. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - September 22, 2016 Category: Opthalmology Authors: Rishi, P., Rishi, E., Bhende, M., Agarwal, V., Vyas, C. H., Valiveti, M., Bhende, P., Rao, C., Susvar, P., Sen, P., Raman, R., Khetan, V., Murali, V., Ratra, D., Sharma, T. Tags: Choroid, Optic nerve, Optics and refraction Original articles - Clinical science Source Type: research

Highlights from this issue
Shah et al (see page 1332) For cystoid macular edema secondary to a retinal vein occlusion, specialists would be more likely to choose bevacizumab, and would be less likely to choose aflibercept than if they were choosing the drug to treat their own disease. Rishi et al (see page 1337) Combination Photodynamic therapy and intravitreal anti-VEGF (Ranibizumab/Bevacizumab) is associated with better outcomes in eyes with myopic CNV as compared to monotherapy with PDT or anti-VEGF. Prünte et al (see page 1341) Switching from a pro re nata (PRN) to treat and extend regimen of ranibizumab in patients with nAMD resulted in signi...
Source: British Journal of Ophthalmology - September 22, 2016 Category: Opthalmology Authors: Barton, K., Chodosh, J., Jonas, J. Tags: At a glance Source Type: research

Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion
AbstractPurposeWe compared the efficacy of bimonthly intravitreal injections of ranibizumab (IVR) with that of bimonthly intravitreal injections of aflibercept (IVA) in two prospective, consecutive groups of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).Patients and MethodsEyes with ME after CRVO received either bimonthly IVR (ranibizumab group;n = 13) or IVA (aflibercept group;n = 13) injections and were followed monthly for 6 months. Three patients in the ranibizumab group and two in the aflibercept group were lost to follow-up and excluded from the study. Th...
Source: Japanese Journal of Ophthalmology - September 22, 2016 Category: Opthalmology Source Type: research

Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients.
CONCLUSION: Ranibizumab was effective in improving BCVA and was well tolerated in Japanese patients with BRVO and CRVO. The findings from this study were consistent with those reported in the Caucasian population. PMID: 27654837 [PubMed - as supplied by publisher] (Source: Acta Med Okayama)
Source: Acta Med Okayama - September 22, 2016 Category: Universities & Medical Training Authors: Kamei M, Terasaki H, Yoshimura N, Shiraga F, Ogura Y, Grotzfeld AS, Pilz S, Ishibashi T Tags: Acta Ophthalmol Source Type: research

Reply
Drs Azad and Takkar have made 3 points regarding the manuscript reporting the 12-month outcomes of the VIBRANT Study. The first is that they feel the study should have used an as-needed dosing regimen rather than bimonthly fixed dosing regimen between months 6 and 12 because this would have provided better information as to how many injections of aflibercept are needed to compare with the number of ranibizumab injections required between 6 and 12 months in the BRAVO study.1,2 There are pros and cons to every treatment regimen. (Source: Ophthalmology)
Source: Ophthalmology - September 21, 2016 Category: Opthalmology Authors: W. Lloyd Clark, David S. Boyer, Jeffrey S. Heier, David M. Brown, Julia A. Haller, Robert Vitti, Husain Kazmi, Alyson J. Berliner, Kristine Erickson, Karen W. Chu, Yuhwen Soo, Yenchieh Cheng, Peter A. Campochiaro Tags: Correspondence Source Type: research

Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study
Vision-related quality of life (vrQoL) is advancing more and more into the focus of interest in ophthalmological clinical research. However, to date only little information is available about vrQoL from large ... (Source: Health and Quality of Life Outcomes)
Source: Health and Quality of Life Outcomes - September 20, 2016 Category: Global & Universal Authors: Thomas Bertelmann, Nicolas Feltgen, Martin Scheffler, Ulrich Hufenbach, Annette Wiedon, Helmut Wilhelm and Focke Ziemssen Source Type: research

Choroidal thickness and visual prognosis in type 1 lesion due to neovascular age-related macular degeneration.
CONCLUSIONS: Thicker subfoveal choroid was associated with better visual outcomes in patients with type 1 CNV due to nAMD following a strict PRN regimen with intravitreal ranibizumab at 24 months of follow-up. PMID: 27646337 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - September 17, 2016 Category: Opthalmology Authors: Hernández-Martínez P, Dolz-Marco R, Hervás-Marín D, Andreu-Fenoll M, Gallego-Pinazo R, Arévalo JF Tags: Eur J Ophthalmol Source Type: research

Early and Long-term Responses to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
To determine whether early visual acuity response to ranibizumab in diabetic macular edema is associated with long-term outcome. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - September 16, 2016 Category: Opthalmology Authors: Victor H. Gonzalez, Joanna Campbell, Nancy M. Holekamp, Szil árd Kiss, Anat Loewenstein, Albert J. Augustin, Julia Ma, Allen C. Ho, Vaishali Patel, Scott M. Whitcup, Pravin U. Dugel Source Type: research

Early and Long-Term Responses to Anti –Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data
To determine whether early visual acuity response to ranibizumab in diabetic macular edema is associated with long-term outcome. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - September 16, 2016 Category: Opthalmology Authors: Victor H. Gonzalez, Joanna Campbell, Nancy M. Holekamp, Szil árd Kiss, Anat Loewenstein, Albert J. Augustin, Julia Ma, Allen C. Ho, Vaishali Patel, Scott M. Whitcup, Pravin U. Dugel Source Type: research

Vitreous and serum VEGF levels after intravitreal injection of bevacizumab, ranibizumab and triamcinolone acetonide in patients with proliferative diabetic retinopathy
PurposeTo compare ocular and systemic vascular endothelial growth factor (VEGF) antagonizing effect of bevacizumab (IVB), ranibizumab (IVR) and triamcinolone acetonide (IVT) following intravitreal injection in eyes with proliferative diabetic retinopathy (PDR). MethodsThirty‐one eyes of 28 patients with diabetic retinopathy and 21 eyes of 21 non‐diabetic patients having various vitreoretinal diseases underwent vitrectomy. Eyes with PDR were injected with IVB (n = 7), IVR (n = 10) or IVT (n = 6) 3 days prior to vitrectomy. The non PDR eyes (n = 8) was not injected. Vitreous a...
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: F.I. Sozen ‐Delil, O. Cekic, G. Haklar Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Licence to save – a UK survey of anti‐VEGF use for the eye in 2015
ConclusionsThese results show the anti‐VEGF injection cost to the NHS. Contrary to hypothesis the vast majority (97%) were still with the more expensive drugs ranibizumab and aflibercept. If all injections used divided bevacizumab, the estimated drug cost would be £607,749 (£729,500 incl. VAT) saving the NHS £449,196,354 (£539,035,492 incl. VAT) per year. With 5% remaining unaccounted for the savings may be greater. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: A. Shalaby, A. Lockwood, A. Bush, K. Lewis, S. Di Simplicio, P. Meredith Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Comparison of efficacy of intravitreal ranibizumab and aflibercept in eyes with diabetic macular edema
PurposeTo compare the efficacy of intravitreal ranibizumab (IVR) and intravitreal aflibercept injection (IVA) injections on diabetic macular edema (DME). MethodsThe medical records of 49 eyes of 36 patients who were diagnosed with DME and had received IVR treatment from March to December 2014 and 46 eyes of 40 patients who had received IVA treatment from December 2014 to October 2015 were reviewed. The IVR and IVA were injected pro re nata. The central macular thickness and best‐corrected visual acuity (BCVA) were measured at 1, 3, and 6 months after the IVR or IVA. The mean number of injections of IVR injections wa...
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: T. Oshitari, N. Shimizu, T. Tatsumi, Y. Takatsuna, M. Arai, E. Sato, S. Yamamoto Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Comparison between Aflibercept, Ranibizumab intravitreal injection on Neovascular Age ‐related macular degeneration patients
ConclusionsFor treatment of neovascular AMD patients, aflibercept might be more effective in serous pigment epithelium detachment than ranibizumab. Because there was no significant visual acuity improvement in serous pigment detachment improvement group in both two treatments, it might be necessary to study further about relationship between visual acuity and serous pigment detachment improvement. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: Y.H. Kwon, J.S. Min, H. Ahn Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Treatment outcome of switching from ranibizumab to aflibercept in patients with central retinal vein occlusion
ConclusionsAflibercept is an efficient alternative treatment for macular oedema secondary to CRVO refractory to ranibizumab. Good anatomic and functional result can be achieved with few injections. The maintenance of these results after 6 months is yet to be investigated. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: V. Konidaris, K. Gorgoli, S. Burgula, J. Deane, S. Banerjee, T. Empeslidis Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Spontaneous anatomical improvement on OCT findings in patients with neovascular age ‐related macular degeneration without anti‐VEGF treatment
ConclusionsThese findings might imply that some patients showing small amount of remaining SRF and/or PED might not need frequent anti‐VEGF injection, especially in patients showing good response to anti‐VEGF therapy with relatively good initial visual acuity. And closed follow up will be essential and needed for those patients. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: K.H. Kim, S.J. Yang Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Changes in choroidal thickness after ranibizumab and aflibercept Therapy for treatment ‐naïve wet age‐related macular degeneration
ConclusionsSubfoveal choroidal thickness was decreased after ranibizumab and aflibercept therapy. The mean changes in subfoveal choroidal thickenss was greater in aflibercept injected group at 1 month, but there was no significant difference between two therapy at 2, 3, and 6 months after initial injection. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: H.G. Kang, J.S. Kim, J.H. Lee, Y.I. Kim, S.H. Lee Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Alterations of retinal vessel size after single injection of intravitreal anti ‐VEGF for diabetic macular edema
PurposeTo determine the affect of single injection of intravitreal anti‐vascular endothelial growth factor on the retinal vessel caliber in eyes with diabetic macular edema. MethodsOverall 32 patients were enrolled in ranibizumab group, 30 patients were included in bevacizumab group. Each of these groups also was divided into two others consisting of study group and control group. The study groups were composed of injected eyes while the non‐injected fellow eyes served as control group. The patients underwent complete ophthalmic examinations including optical coherence tomography and fundus fluorescein angiography. The...
Source: Acta Ophthalmologica - September 14, 2016 Category: Opthalmology Authors: C. Akpolat, M. Kurt, O. Cekic Tags: Abstracts from the 2016 European Association for Vision and Eye Research Conference Source Type: research

Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service setting
To determine visual acuity (VA) and spectral domain optical coherence tomography (OCT) outcomes with intravitreal ranibizumab for diabetic macular edema (DME) in a United Kingdom National Health Service clinical setting. (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - September 13, 2016 Category: Opthalmology Authors: Namritha V. Patrao, Sheelah Antao, Catherine Egan, Amer Omar, Robin Hamilton, Philip G. Hykin, Sobha Sivaprasad, Ranjan Rajendram, Moorfields diabetic macular edema study group Source Type: research

[Ranibizumab and exudative age-related macular degeneration: 5-year multicentric functional and anatomical results in real-life practice].
Authors: Boulanger-Scemama E, Sayag D, Ha Chau Tran T, Quaranta-El Maftouhi M, Rumen F, Creuzot-Garcher C, Blanco Garavito R, Jung C, Souied E Abstract PURPOSE: The goal of this study was to evaluate five year functional and anatomical outcomes of wet AMD patients treated with ranibizumab according to a pro re nata (PRN) regimen in real-life practice. METHODS: A retrospective, multicentric chart review of 201 eyes of 201 patients who underwent their first ranibizumab intravitreal injection (IVT) between January 1, 2007 and December 31, 2008 was performed. Best-corrected visual acuity (BCVA), central macular thi...
Source: Journal Francais d Ophtalmologie - September 11, 2016 Category: Opthalmology Tags: J Fr Ophtalmol Source Type: research

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity
ABSTRACT Normal-tension glaucoma (NTG) is a progressive optic neuropathy with intraocular pressure (IOP) within the statistically normal range ( ≤ 21 mmHg). The prevalence of NTG varies widely among different population studies, being the most prevalent open-angle glaucoma subtype in some reports. The etiology of NTG possibly is multifactorial and still not well defined. Alternative treatments have been proposed based on pathogenesis details. However, in clinical practice, adequate reduction of IOP remains the keystone of managing patients with NTG. We review the pathogenesis of NTG and the available therapies for this ...
Source: Arquivos Brasileiros de Oftalmologia - September 9, 2016 Category: Opthalmology Source Type: research

Ranibizumab for the treatment of wet AMD: a summary of real-world studies
Eye advance online publication, September 9 2016.doi:10.1038/eye.2016.202Author: V Chong (Source: Eye)
Source: Eye - September 9, 2016 Category: Opthalmology Authors: V Chong Source Type: research

UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV
To study the incidence of blindness and sight impairment in treatment-naive patients receiving ranibizumab (Lucentis) for neovascular age-related macular degeneration (nAMD) in the United Kingdom (UK) National Health Service. (Source: Ophthalmology)
Source: Ophthalmology - September 9, 2016 Category: Opthalmology Authors: Robert L. Johnston, Aaron Y. Lee, Miranda Buckle, Richard Antcliff, Clare Bailey, Martin McKibbin, Usha Chakravarthy, Adnan Tufail, UK AMD EMR Users Group Source Type: research

Retinal proteome changes following experimental branch retinal vein occlusion and intervention with Ranibizumab.
B, Vorum H Abstract Animal models of experimental branch retinal vein occlusion (BRVO) provide a unique opportunity to study protein changes directly in retinal tissue. Results from these experimental models suggest that experimental BRVO is associated with an upregulation of extracellular matrix remodeling and adhesion signaling processes. To study whether these processes could be blocked by inhibition of VEGF-A, a porcine model of experimental BRVO was combined with proteomic analyses. In six Danish Landrace pigs experimental BRVO was induced with argon laser in both eyes. After 24 h an injection of 0.05&n...
Source: Experimental Eye Research - September 9, 2016 Category: Opthalmology Authors: Cehofski LJ, Kruse A, Bøgsted M, Magnusdottir SO, Stensballe A, Honoré B, Vorum H Tags: Exp Eye Res Source Type: research

[Correction: Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results].
Authors: Pfau M, Fassnacht-Riederle HM, Freiberg FJ, Wons JB, Wirth M, Becker MD, Michels S PMID: 27599047 [PubMed - as supplied by publisher] (Source: Klinische Monatsblatter fur Augenheilkunde)
Source: Klinische Monatsblatter fur Augenheilkunde - September 8, 2016 Category: Opthalmology Tags: Klin Monbl Augenheilkd Source Type: research

Study of stability and biophysical characterization of ranibizumab and aflibercept.
Abstract The anti-vascular endothelial growth factor (VEGF) agents such as ranibizumab (Lucentis®) and aflibercept (EyLea®) are currently used as monthly or bimonthly intravitreal injections to treat potentially blinding retinal diseases such as wet age-related macular degeneration (AMD) or diabetic macular edema (DME). Because of the complications associated with repeated intra-vitreal injections, there is considerable interest in developing a sustained delivery system. The purpose of this study was to examine the stability of both therapeutic proteins under physiological conditions as well as when incorp...
Source: European Journal of Pharmaceutics and Biopharmaceutics - September 8, 2016 Category: Drugs & Pharmacology Authors: Moreno MR, Tabitha TS, Nirmal J, Radhakrishnan K, Yee CH, Lim S, Venkatraman S, Agrawal R Tags: Eur J Pharm Biopharm Source Type: research

Treatment of Retinitis Pigmentosa-Associated Cystoid Macular Oedema Using Intravitreal Aflibercept (Eylea) despite Minimal Response to Ranibizumab (Lucentis): A Case Report
Conclusions: This is the first case report to demonstrate a reduction of RP-associated CMO following intravitreal aflibercept, despite inadequate response to ranibizumab on two separate occasions. Aflibercept may provide superior action to other anti-VEGF medications due to its intermediate size (115 kDa) and higher binding affinity. This is worthy of further investigation in a large prospective cohort over an extended time to determine the safety and efficacy of intravitreal aflibercept for use in this condition.Case Rep Ophthalmol 2016;7:389 –397 (Source: Case Reports in Ophthalmology)
Source: Case Reports in Ophthalmology - September 7, 2016 Category: Opthalmology Source Type: research

Intravitreal ranibizumab for retinal arterial macroaneurysm: long-term results of a prospective study.
CONCLUSIONS: Intravitreal ranibizumab seems to be effective and safe for the treatment of symptomatic RAM. PMID: 27646333 [PubMed - as supplied by publisher] (Source: European Journal of Ophthalmology)
Source: European Journal of Ophthalmology - September 7, 2016 Category: Opthalmology Authors: Chatziralli I, Maniatea A, Koubouni K, Parikakis E, Mitropoulos P Tags: Eur J Ophthalmol Source Type: research

Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration
To analyze the effect of baseline presence and height of pigment epithelial detachments (PEDs) on visual and anatomic outcomes at 24 months in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab. (Source: Ophthalmology)
Source: Ophthalmology - August 26, 2016 Category: Opthalmology Authors: David Sarraf, Nikolas J.S. London, Rahul N. Khurana, Pravin U. Dugel, Shamika Gune, Lauren Hill, Lisa Tuomi Source Type: research

Punctate inner choroidopathy complicated with exudative neurosensory detachment: A favourable response to treatment with systemic corticosteroids and intravitreal ranibizumab.
DISCUSSION: Intravitreal ranibizumab, associated with systemic corticosteroids, may be an effective treatment for exudative neurosensory detachment complicating PIC. PMID: 27555066 [PubMed - as supplied by publisher] (Source: Archivos de la Sociedad Espanola de Oftalmologia)
Source: Archivos de la Sociedad Espanola de Oftalmologia - August 25, 2016 Category: Opthalmology Tags: Arch Soc Esp Oftalmol Source Type: research

Short-term effect of intravitreal ranibizumab therapy on macular edema after branch retinal vein occlusion
Purpose: To assess the short-term effect of intravitreal ranibizumab (IVR) on macular edema after branch retinal vein occlusion. Methods: Twenty-three eyes with macular edema after branch retinal vein occlusion were enrolled in a prospective observational study. After administering one IVR injection (0.5 mg) for the first time, the authors measured the foveal thickness (FT) before and 2 hours, 1 and 3 days, 1 week, and 1 month later and the best-corrected visual acuity at all times except 2 hours, and determined the changes from baseline (ΔFT and ΔVA). Results: The mean FT decreased significantly (P (Source: RETINA)
Source: RETINA - August 24, 2016 Category: Opthalmology Tags: Original Study Source Type: research

Effect of intravitreal ranibizumab injection on aqueous humour cytokine levels in patients with diabetic macular oedema
(Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - August 22, 2016 Category: Opthalmology Authors: Tomoyasu Shiraya, Satoshi Kato, Fumiyuki Araki, Takashi Ueta Tags: Letter to the Editor Source Type: research

Short-term effect of aflibercept on visual acuity and central macular thickness in patients not responding to ranibizumab and bevacizumab.
CONCLUSION: Aflibercept results in improvement in CMT in non-responders to ranibizumab and bevacizumab as long as therapy is given continuously and can therefore be an alternative therapy. PMID: 27550436 [PubMed - as supplied by publisher] (Source: Wiener Klinische Wochenschrift)
Source: Wiener Klinische Wochenschrift - August 22, 2016 Category: Journals (General) Authors: Maksys S, Richter-Müksch S, Weingessel B, Vécsei-Marlovits PV Tags: Wien Klin Wochenschr Source Type: research

Variation in Visual Outcome to Anti-Vascular Endothelial Growth Factors in Choroidal Neovascular Membrane Developing in Eyes with Previously Untreated Versus Focal Laser-Treated Central Serous Chorioretinopathy.
Authors: Roy R, Saurabh K, Das D, Panigrahi PK, Das S, Pal SS, Jain A Abstract PURPOSE: To report the visual outcome in choroidal neovascular membrane developing (CNVM) in eyes with central serous chorioretinopathy (CSCR) with our without prior focal laser. METHODS: A retrospective case series of eyes with CNVM secondary to CSCR treated with intravitreal anti-VEGF. RESULTS: Ten eyes of nine patients of CNVM with CSCR who underwent intravitreal anti-VEGF injections were analyzed. Five eyes had CNVM without prior laser photocoagulation, and five eyes developed CNVM after laser photocoagulation for CSCR. Intra...
Source: Seminars in Ophthalmology - August 19, 2016 Category: Opthalmology Tags: Semin Ophthalmol Source Type: research

Phase IIb clinical trial of ranibizumab for the treatment of uveitic and idiopathic choroidal neovascular membranes
Conclusion Patients gained vision (mean of 21 letters at 12 months) and showed reduced CST. These results support the continued use of ranibizumab in the treatment of iCNV. Trial registration number 2008-007476-19, results. (Source: British Journal of Ophthalmology)
Source: British Journal of Ophthalmology - August 17, 2016 Category: Opthalmology Authors: Carreno, E., Moutray, T., Fotis, K., Lee, R. W. J., Dick, A. D., Ross, A. H., Bailey, C. Tags: Original articles - Clinical science Source Type: research

Classification of diabetic macular oedema using ultra-widefield angiography and implications for response to anti-VEGF therapy.
CONCLUSIONS: UWFA facilitates the detection of peripheral ischaemia, which is associated with a significant proportion of DMO. While this group of DMO responded well to anti-VEGF therapy, it remains to be determined whether addressing the peripheral ischaemia may reduce recurrence. PMID: 27531355 [PubMed - as supplied by publisher] (Source: The British Journal of Ophthalmology)
Source: The British Journal of Ophthalmology - August 16, 2016 Category: Opthalmology Authors: Xue K, Yang E, Chong NV Tags: Br J Ophthalmol Source Type: research

Panretinal Photocoagulation versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes from a Randomized Clinical Trial
Compare patient-centered outcomes in patients with proliferative diabetic retinopathy (PDR) treated with ranibizumab versus panretinal photocoagulation (PRP). (Source: American Journal of Ophthalmology)
Source: American Journal of Ophthalmology - August 11, 2016 Category: Opthalmology Authors: Wesley T. Beaulieu, Neil M. Bressler, Michele Melia, Cynthia Owsley, Calvin E. Mein, Jeffrey G. Gross, Lee M. Jampol, Adam R. Glassman, Diabetic Retinopathy Clinical Research Network Source Type: research

Comparison of Perioperative Ranibizumab Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery.
Conclusions. Although intrapostoperative ranibizumab injection for DME seems to be more effective than preoperative injections in patients undergoing cataract surgery, the treatment still needs to be continued following surgery. PMID: 27493795 [PubMed] (Source: Journal of Ophthalmology)
Source: Journal of Ophthalmology - August 8, 2016 Category: Opthalmology Tags: J Ophthalmol Source Type: research

Efficacy of Topical O floxacin 0.3 % Administration on Conjunctival Bacterial Flora in Diabetic Patients Undergoing Intravitreal Injections.
CONCLUSIONS: The combined one day/one hour (eight doses) ofloxacin administration in diabetic patients is extremely effective in reducing conjunctival bacterial flora. The application of topical ofloxacin for one day or one hour before IVI is also significantly effective. PMID: 27487463 [PubMed - as supplied by publisher] (Source: Seminars in Ophthalmology)
Source: Seminars in Ophthalmology - August 5, 2016 Category: Opthalmology Tags: Semin Ophthalmol Source Type: research

High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration.
This study investigated the efficacy and safety of high dose anti-VEGF (HDAV) for refractory PED. METHODS: In this retrospective study, 31 eyes of neovascular age-related macular degeneration patients with persistent PED findings despite six or more intravitreal injections of CDAV (bevacizumab 1.25 mg or ranibizumab 2.5 mg) were analyzed. Changes in visual outcome, central foveal thickness, and PED height were compared before and after HDAV (bevacizumab 5.0 mg) for these refractory PED cases. RESULTS: The mean age of patients was 67.7 years. The number of CDAV injections was 12.1. The number of HDAV injections was ...
Source: Korean Journal of Ophthalmology : KJO - August 3, 2016 Category: Opthalmology Tags: Korean J Ophthalmol Source Type: research

Change of retinal pigment epithelial atrophy after anti-vascular endothelial growth factor treatment in exudative age-related macular degeneration
Conclusions: RPE atrophy progresses in eyes with exudative AMD during anti-VEGF treatment. Larger areas of RPE atrophy at month 4 and larger numbers of anti-VEGF injections were associated with an increased risk of progression of RPE atrophy the following treatment. These findings may be useful to clinicians using intravitreal anti-VEGF for the treatment of exudative AMD, both for selecting an appropriate treatment plan and for predicting the progression of RPE atrophy. (Source: Indian Journal of Ophthalmology)
Source: Indian Journal of Ophthalmology - August 3, 2016 Category: Opthalmology Authors: Moosang Kim Eung Suk Kim Kyung Hoon Seo Seung-Young Yu Hyung-Woo Kwak Source Type: research

Cost ‐effectiveness of treating wet age‐related macular degeneration at the Kuopio University Hospital in Finland based on a two‐eye Markov transition model
ConclusionA two‐eye Markov transition model was developed to analyse the cost‐effectiveness of wet AMD treatment, as quality of life years (QALYs) are largely based on the visual acuity of the better‐seeing eye. Monthly injected bevacizumab was the most cost‐effective treatment and monthly ranibizumab the least effective. (Source: Acta Ophthalmologica)
Source: Acta Ophthalmologica - August 2, 2016 Category: Opthalmology Authors: Pasi Vottonen, Eila Kankaanp ää Tags: Original Article Source Type: research

Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema
This study uses data from the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial to examine the incremental cost-effectiveness ratios of aflibercept, bevacizumab, and ranibizumab for the treatment of diabetic macular edema. (Source: JAMA Ophthalmology)
Source: JAMA Ophthalmology - August 1, 2016 Category: Opthalmology Source Type: research